Business Context and Reporting Period
This Form 8-K was filed by EFoodSafety.com, Inc. (noted as Pharmacyte Biotech, Inc. in metadata) on August 9, 2004. The report details the completion of a private financing round involving the sale of convertible debentures to institutional investors.
Key Financial Metrics
- Financing Proceeds: $2,000,000 in gross proceeds received at closing.
- Instrument Type: 6% convertible debentures.
- Conversion Price: $0.40 per share of common stock.
- Warrant Terms: For every two shares of common stock convertible, investors received two warrants: one exercisable at $0.80 per share and one at $1.00 per share.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, margins, or existing debt levels outside of this new issuance.
Material Changes
The primary material change is the increase in liquidity through the $2.0 million private placement. The company has incurred a new debt obligation with a 6% interest rate and potential equity dilution upon conversion or warrant exercise. No prior comparable period financial data is provided in this specific filing to quantify changes in operating metrics.
Guidance, Risks, and Contingencies
- Registration Obligations: The Company must file a registration statement within 30 days of the closing and have it declared effective within 90 days of filing.
- Penalty Clauses: If the Company fails to meet registration deadlines, it must pay cash penalties equal to 2% of the purchase price. If the failure continues beyond 30 days, an additional 2% penalty applies, with further 2% payments due for continued failure.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ significantly from anticipated results due to risks and uncertainties.
- Investor Base: The offering was limited to a very small group of accredited investors, including Longwood Capital, LLC.
Investor Verification Checklist
- Verify the company's current cash position and burn rate to assess the runway provided by the $2.0 million proceeds.
- Confirm the status of the registration statement filing required within 30 days of August 9, 2004, to avoid penalty payments.
- Calculate the potential dilution impact based on the $0.40 conversion price and the warrant strike prices of $0.80 and $1.00.
- Review the full "Form of Note and Warrant Purchase Agreement" (Exhibit 10.1) for additional covenants or restrictions not summarized here.